Determining the duration of therapy for patients with community-acquired pneumonia.

about

Current treatment of community-acquired pneumonia.

P2860

Q38105639-ACBDDEFD-8B20-4FD6-A163-F712C9459F15

P2860

Determining the duration of therapy for patients with community-acquired pneumonia.

Item

http://www.wikidata.org/entity/Q48554490

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Determining the duration of therapy for patients with community-acquired pneumonia.

@en

Determining the duration of therapy for patients with community-acquired pneumonia.

@nl

type

Item

label

Determining the duration of therapy for patients with community-acquired pneumonia.

@en

Determining the duration of therapy for patients with community-acquired pneumonia.

@nl

prefLabel

Determining the duration of therapy for patients with community-acquired pneumonia.

@en

Determining the duration of therapy for patients with community-acquired pneumonia.

@nl

P1476

Determining the duration of therapy for patients with community-acquired pneumonia.

@en

P2093

Nikole M Scalera

http://www.w3.org/2001/XMLSchema#string

Thomas M File

http://www.w3.org/2001/XMLSchema#string

P2860

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections

Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis

Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis

Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis.

Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial.

Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.

Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study.

Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators.

P304

191-195

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11908-013-0327-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23443362

http://www.w3.org/2001/XMLSchema#string

Determining the duration of therapy for patients with community-acquired pneumonia.

about

P2860

P2860

Determining the duration of therapy for patients with community-acquired pneumonia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698